Active, not recruitingPhase 3NCT05730699
Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)
Studying Neuromyelitis Optica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biocad
- Intervention
- divozilimab(biological)
- Enrollment
- 105 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (19)
- Llc "Profimed", Barnaul, Russia
- Municipal Autonomous Healthcare Institution of the Order of the Red Banner of Labor "City Clinical Hospital No.1", Chelyabinsk, Russia
- Regional Clinical Hospital No.3, Chelyabinsk, Russia
- Kuzbass Clinical Hospital named after S.V. Belyaev, Kemerovo, Russia
- Khanty-Mansiysk autonomous district - Ugra "The district clinical hospital", Khanty-Mansiysk, Russia
- Center for Cardiology and Neurology, Kirov, Russia
- Regional Clinical Hospital № 1 named after Professor S. V. Ochapovsky, Krasnodar, Russia
- Moscow Regional Clinical Research Institute named after M.F. Vladimirsky (MONIKI), Moscow, Russia
- LLC "Medis", Nizhny Novgorod, Russia
- Semashko Regional Clinical Hospital, Nizhny Novgorod, Russia
- State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russia
- Pyatigorsk City Clinical Hospital No.2, Pyatigorsk, Russia
- Federal State Budgetary Educational Institution of Higher Education "Rostov State Medical University", Rostov-on-Don, Russia
- Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia
- Seredavin Regional Clinical Hospital, Samara, Russia
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05730699 on ClinicalTrials.govOther trials for Neuromyelitis Optica
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT05909761Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During PregnancyAmgen
- RECRUITINGPHASE3NCT05199688A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)Hoffmann-La Roche
- RECRUITINGPHASE4NCT07420296Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderTianjin Medical University General Hospital
- RECRUITINGNCT06885957Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSDTongji Hospital
- RECRUITINGPHASE1NCT06620809The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum DisordersTongji Hospital
- RECRUITINGNANCT06865274Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNANCT06780709Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSDIcahn School of Medicine at Mount Sinai
- ACTIVE NOT RECRUITINGPHASE3NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDAlexion Pharmaceuticals, Inc.